EUVIMEDEUVIMED entdecken
Crossref

Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade

Habib Hamidi, Yasin Senbabaoglu, Niha Beig, Juliette Roels, Cyrus Manuel, Xiangnan Guan, Hartmut Koeppen, Zoe June Assaf, Barzin Y Nabet, Adrian Waddell, Kobe Yuen, Sophia Maund und 21 weitere

Cancer Cell · 2024-12 · 42 (12) · 2098-2112.e4

DOI: 10.1016/j.ccell.2024.10.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cell, 2024-12. Verfasst von Habib Hamidi und 32 weiteren Autor:innen. Beteiligte Einrichtung: Genentech, South San Francisco CA, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, B7-H1 Antigen, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: F. Hoffmann-La Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Checkpoint inhibitors targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) have revolutionized cancer therapy across many indications including urothelial carcinoma (UC). Because many patients do not benefit, a better understanding of the molecular mechanisms underlying response and resistance is needed to improve outcomes. We profiled tumors from 2,803 UC patients from four late-stage randomized clinical trials evaluating the PD-L1 inhibitor atezolizumab by RNA sequencing (RNA-seq), a targeted DNA panel, immunohistochemistry, and digital pathology. Machine learning identifies four transcriptional subtypes, representing luminal desert, stromal, immune, and basal tumors. Overall survival benefit from atezolizumab over standard-of-care is observed in immune and basal tumors, through different response mechanisms. A self-supervised digital pathology approach can classify molecular subtypes from H&E slides with high accuracy, which could accelerate tumor molecular profiling. This study represents a large integration of UC molecular and clinical data in randomized trials, paving the way for clinical studies tailoring treatment to specific molecular subtypes in UC and other indications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsB7-H1 AntigenAntibodies, Monoclonal, HumanizedHumansUrinary Bladder NeoplasmsCarcinoma, Transitional CellMaleFemaleBiomarkers, TumorGenetic HeterogeneityAged

Stichwörter der Autor:innen

PD-L1 blockadedigital pathologymolecular heterogeneitypatient stratificationtranscriptomicsurothelial carcinoma

Substanzen

Immune Checkpoint InhibitorsatezolizumabB7-H1 AntigenAntibodies, Monoclonal, HumanizedCD274 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Genentech, South San Francisco CA, USA.
  • Foundation Medicine, Cambridge MA, USA.
  • Institut de Cancérologie Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Dana Farber Cancer Institute, Boston MA, USA.
  • Fred Hutchinson Cancer Center, Seattle WA, USA.
  • Memorial Sloan Kettering Cancer Center, New York NY, USA.

Förderung

  • F. Hoffmann-La Roche

Zitieren

APA

Hamidi, H., Senbabaoglu, Y., Beig, N., Roels, J., Manuel, C., Guan, X., Koeppen, H., Assaf, Z. J., Nabet, B. Y., Waddell, A., Yuen, K., Maund, S., Sokol, E., Giltnane, J. M., Schedlbauer, A., Fuentes, E., Cowan, J. D., Kadel, E. E., Degaonkar, V., …, & Banchereau, R. (2024). Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade. Cancer Cell, 42(12), 2098-2112.e4. https://doi.org/10.1016/j.ccell.2024.10.016

Vancouver

Hamidi H, Senbabaoglu Y, Beig N, Roels J, Manuel C, Guan X, et al. Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade. Cancer Cell. 2024;42(12):2098-2112.e4. doi:10.1016/j.ccell.2024.10.016

BibTeX
@article{Hamidi2024,
  author = {Hamidi, Habib and Senbabaoglu, Yasin and Beig, Niha and Roels, Juliette and Manuel, Cyrus and Guan, Xiangnan and Koeppen, Hartmut and Assaf, Zoe June and Nabet, Barzin Y and Waddell, Adrian and Yuen, Kobe and Maund, Sophia and Sokol, Ethan and Giltnane, Jennifer M and Schedlbauer, Amber and Fuentes, Eloisa and Cowan, James D and Kadel, Edward E and Degaonkar, Viraj and Andreev-Drakhlin, Alexander and Williams, Patrick and Carter, Corey and Gupta, Suyasha and Steinberg, Elizabeth and Loriot, Yohann and Bellmunt, Joaquim and Grivas, Petros and Rosenberg, Jonathan and van der Heijden, Michiel S and Galsky, Matthew D and Powles, Thomas and Mariathasan, Sanjeev and Banchereau, Romain},
  title = {Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade},
  journal = {Cancer Cell},
  year = {2024},
  volume = {42},
  number = {12},
  pages = {2098--2112.e4},
  doi = {10.1016/j.ccell.2024.10.016}
}
Kostenlos starten →